Meeting NewsVideo

VIDEO: Canagliflozin protects kidney function across GFR-spectrum

WASHINGTON — In a secondary analysis of the CREDENCE trial presented here at ASN Kidney Week, researchers focused on subgroups of different GFRs. They determined canagliflozin is safe and effective even for patients with eGFR of 30 mL/min/1.73m2 to less than 45 mL/min/1.73m2.

“The bottom line is that the benefit is clearly not glucose dependent and certainly not diuretic dependent,” George L. Bakris, MD, FASN, FAHA, professor of medicine and director of the American Heart Association’s Comprehensive Hypertension Center at the University of Chicago Medicine, told Healio Nephrology in a video exclusive. “This drug protects the kidney across all spectrum of GFR down to stage 4 CKD and provides cardiovascular risk reduction, especially [for] heart failure.”

WASHINGTON — In a secondary analysis of the CREDENCE trial presented here at ASN Kidney Week, researchers focused on subgroups of different GFRs. They determined canagliflozin is safe and effective even for patients with eGFR of 30 mL/min/1.73m2 to less than 45 mL/min/1.73m2.

“The bottom line is that the benefit is clearly not glucose dependent and certainly not diuretic dependent,” George L. Bakris, MD, FASN, FAHA, professor of medicine and director of the American Heart Association’s Comprehensive Hypertension Center at the University of Chicago Medicine, told Healio Nephrology in a video exclusive. “This drug protects the kidney across all spectrum of GFR down to stage 4 CKD and provides cardiovascular risk reduction, especially [for] heart failure.”

    See more from American Society of Nephrology Annual Meeting